Search Results

How to Deal with Goliath: Your Myeloma Diagnosis

Guest blogger Yelak talks about leading and directing your medical team

Who is Goliath? Goliath, in the Bible, was a giant who couldn’t be defeated because of his huge size and power. In our world of myeloma today, Goliath is the might of medical care, medical insurance, treatment options, clinical trials and all the daunting tasks of living and dealing with myeloma.

Pralatrexate

Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.

Surviving AML: The Long Road Back

“Hola,” I said playfully, as I answered my cell phone on a beautiful Saturday -- April 21, 2012. “This is Dr. so and so. I’m calling because your blood work from yesterday is all out of whack.” “What do you mean, ‘Out of whack?’” “Your white blood cell count is high,” he said. “What’s high? “It's at 63,000.” “And what's it supposed to be?” “10,000.”

Zebrafish: A New Way to Study Leukemia

David Traver, Ph.D., a professor of Cellular and Molecular Medicine at the University of California, San Diego, is the recipient of an LLS Career Development Program (CDP) grant. Traver’s research laboratory is using the zebrafish as a model to study the biology of cancer.

Leucovorin

Leucovorin is an FDA-approved drug similar to the vitamin folic acid. It protects healthy cells from the effects of methotrexate while allowing methotrexate to enter and kill cancer cells.

Levoleucovorin (Fusilev®) is a form of leucovorin that is given intravenously (IV).

Predisposing factors to leukemia

Table of contents:

FDA Approves New Targeted Treatment Option for Certain Forms of Acute Myeloid Leukemia in Adults

An older, white man smiles and is joined by his wife, who is also white, as he speaks to his doctor

People with CLL are living longer than ever before, and cures are on the horizon

People with the most common type of blood cancer, chronic lymphocytic leukemia (CLL), are living longer than ever before without their disease progressing. While cures for CLL patients are still rare, survival rates have improved steadily over the last 50 years, with nearly 90 percent of people diagnosed with CLL today surviving at least five years, and most for many years longer.

Meet the Researcher: Maria Figueroa, MD

Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancer, and what inspires their efforts to find better treatments and cures. Dr. Maria “Ken” Figueroa, Associate Professor and Co-Leader of the Cancer Epigenetics Research Program at Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, is focused on an exciting area of research called epigenetics.

Raising Our Voices

A New CAR-T Approval Brings Hope for Mantle Cell Lymphoma Patients

The U.S. Food and Drug Administration (FDA) today announced its approval for a breakthrough treatment that will bring the promise of immunotherapy and new hope to thousands of patients diagnosed with mantle cell lymphoma (MCL) whose previous treatments fail to bring them lasting remissions.

Small Steps Make Big Impact for Moms In Training

Getting the courage to work out is often harder than the workout itself. This is especially true when fitness plans include goals that are hard to measure. Fortunately, through a special partnership with Fitbit, many women in The Leukemia & Lymphoma Society's (LLS) Moms In Training program are learning to better manage their workouts and track their progress.

Cobimetinib

Cobimetinib is indicated as a single agent for the treatment of adult patients with histiocytic neoplasms.

Stopping Gleevec to Start a Family

Erin Zammett Ruddy is a magazine journalist and blogger who was diagnosed with chronic myeloid leukemia at age 23. Today, she is a 40-year-old mother of three.

On January 30 I turned 40. The big 4-0! My grandma Adele and I shared a birthday, and she’d be aghast if she knew I was telling all of you my real age right now. Grandma Del was a Radio City Rockette and very glamorous—and she never turned a day over 29, despite living to 85 (sorry, Grandma). But I am damn proud of being 40, newly-formed wrinkles and all.

Immunotherapies on a Roll at #ASH20

More than three years after the first chimeric antigen receptor (CAR) T-cell therapy achieved U.S. Food and Drug Administration (FDA) approval, the revolutionary approach that has upended blood cancer treatment continues to generate excitement.

Nutrition Advice from a Dietitian & Blood Cancer Survivor

76-year-old Barbara Borrell is a woman who wears many hats – a 50+ year registered dietitian, nutrition consultant and educator, cancer advocate, volunteer with The Leukemia & Lymphoma Society, and a blood cancer survivor who has battled not one, not two, but three types of blood cancer.

FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma

Meet the Researcher: Omar Abdel-Wahab, MD

This is part of a periodic series of Q&A’s with LLS-funded researchers. Dr. Abdel-Wahab of Memorial Sloan Kettering Cancer Center focuses on an area of research called epigenetics – chemical modifications that regulate (switch on and off) gene activity. He is studying how these processes drive the development of acute myeloid leukemia and other blood cancers. He currently holds a Career Development Program grant from LLS, a program that supports scientists earlier in their careers.

Q. What is the focus of your research and its primary goal?